1. Levi M, Cohn DM, Zeerleder S. Hereditary angioedema: linking complement regulation to the coagulation system. Res Pract Thromb Haemost. 2019;3(1):38–43.
2. BioCryst Pharmaceuticals. BioCryst announces FDA approval of ORLADEYO™ (berotralstat), first oral, once-daily therapy to prevent attacks in hereditary angioedema patients [media release]. 3 Dec 2020. https://ir.biocryst.com/.
3. BioCryst. Berotralstat (ORLADEYO™): US prescribing information. 2020. https://orladeyo.com/. Accessed 21 Jan 2020.
4. BioCryst Pharmaceuticals. BioCryst announces approval of ORLADEYO™ (berotralstat) in Japan for the prophylactic treatment of hereditary angioedema [media release]. 22 Jan 2020. https://ir.biocryst.com/.
5. Torii Pharmaceutical. Berotralstat (ORLADEYO™): Japanese prescribing information [Japanese]. 2021. https://www.pmda.go.jp. Accessed 2 Feb 2021.